The influence of the 1997 updated classification criteria for systemic lupus erythematosus: Epidemiology, disease presentation, and patient management

Journal of Rheumatology

Volumn 36, Issue 3, 2009, Pages 552-559

  Eilertsen, Gro Østli ^a   Becker Merok, Andrea ^a   Nossent, Johannes C ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Classification criteria; Diagnosis; Epidemiology; Patient care; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; WARFARIN; ANTIRHEUMATIC AGENT;

ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTHRITIS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NORWAY; OUTCOME ASSESSMENT; PATIENT CARE; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; RASH; RHEUMATOLOGY; SEROLOGY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDITY; AGED; CLINICAL PRACTICE; HOSPITALIZATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MIDDLE AGED; RISK;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; NORWAY; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 65649129348     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080574     Document Type: Article

References (48)

1. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-243 (Pubitemid 27398022)
2. Klippel JH. Systemic lupus erythematosus: demographics, prognosis, and outcome. J Rheumatol 1997;24 Suppl 48:67-71. (Pubitemid 27223603)
3. Gudmundsson S, Steinsson K. Systemic lupus erythematosus in Iceland 1975 through 1984. A nationwide epidemiological study in an unselected population. J Rheumatol 1990;17:1162-1167
4. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-558
5. Nossent HC. Systemic lupus erythematosus in the Arctic region of Norway. J Rheumatol 2001;28:539-546 (Pubitemid 32202656)
6. Voss A, Green A, Junker P. Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort. Scand J Rheumatol 1998;27:98-105. (Pubitemid 28172565)
7. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004;3:423-453 (Pubitemid 39194631)
8. Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 1985;28:80-86
9. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42:46-50.
10. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000;27:685-691 (Pubitemid 30151347)
11. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277 (Pubitemid 13221242)
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
13. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep 2007;9:212-218 (Pubitemid 46954779)
14. Gomez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006;35:322-332
15. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
16. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-27
17. Koike T, Bohgaki M, Amengual O, Atsumi T. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 2007;28:129-133 (Pubitemid 46670690)
18. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1955;1:12-32.
19. Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus 2007;16:309-317
20. Arce-Salinas A, Cardiel MH, Guzman J, Alcocer-Varela J. Validity of retrospective disease activity assessment in systemic lupus erythematosus. J Rheumatol 1996;23:846-849 (Pubitemid 26157760)
21. Bernatsky S, Clarke A, Abrahamowicz M, Neville C, Karp I, Pineau CA. A comparison of prospective and retrospective evaluations of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. J Rheumatol 2005;32:820-823 (Pubitemid 40676489)
22. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-1190
23. Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990;29:185-188 (Pubitemid 20194017)
24. Deligny C, Thomas L, Dubreuil F, et al. [Systemic lupus erythematosus in Martinique: an epidemiologic study]. Rev Med Interne 2002;23:21-29
25. Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985;60:105-113
26. Pelkonen PM, Jalanko HJ, Lantto RK, et al. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol 1994;21:2143-2146 (Pubitemid 24352367)
27. Nossent H, Rekvig OP. Antinuclear antibody screening in this new millennium: farewell to the microscope? Scand J Rheumatol 2001;30:123-126
28. Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP. Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 2004;63:386-394 (Pubitemid 38453304)
29. Neogi T, Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 2006;33:1785-1788 (Pubitemid 44373212)
30. Riboldi P, Gerosa M, Moroni G, et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 2005;38:39-45.
31. Rekvig OP, Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis Rheum 2003;48:300-312
32. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-1533 (Pubitemid 37255038)
33. Alarcon-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-454 (Pubitemid 36278013)
34. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-1599
35. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995;22:1265-1270
36. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-2557 (Pubitemid 44205016)
37. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006;85:147-156 (Pubitemid 43833013)
38. McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004;50:1226-1232 (Pubitemid 38480833)
39. Hereng T, Lambert M, Hachulla E, et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 2008;17:11-15
40. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995;22:1259-1264
41. Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:66-71. (Pubitemid 34518083)
42. Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002;61:1065-1070 (Pubitemid 35397352)
43. Alamanos Y, Voulgari PV, Papassava M, Tsamandouraki K, Drosos AA. Survival and mortality rates of systemic lupus erythematosus patients in northwest Greece. Study of a 21-year incidence cohort. Rheumatology Oxford 2003;42:1122-1123
44. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 1995;38:1492-1499
45. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-225
46. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 1997;24:1061-1065 (Pubitemid 27250109)
47. Abu-Shakra M, Gladman DD, Urowitz MB. Mortality studies in SLE: how far can we improve survival of patients with SLE. Autoimmun Rev 2004;3:418-420 (Pubitemid 39194629)
48. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-415 (Pubitemid 27084212)